Journal
EMBO MOLECULAR MEDICINE
Volume 11, Issue 6, Pages -Publisher
WILEY
DOI: 10.15252/emmm.201809034
Keywords
antihistamine; glioma; LMP; MDGI; PUFA
Categories
Funding
- Ida Montin foundation
- Oskar Offlund foundation
- K. Albin Johansson foundation
- Finnish Cancer Organizations
- Jane & Aatos Erkko Foundation
- Sigrid Juselius Foundation
- Doctoral Programme in Biomedicine
Ask authors/readers for more resources
The current clinical care of glioblastomas leaves behind invasive, radio- and chemo-resistant cells. We recently identified mammary-derived growth inhibitor (MDGI/FABP3) as a biomarker for invasive gliomas. Here, we demonstrate a novel function for MDGI in the maintenance of lysosomal membrane integrity, thus rendering invasive glioma cells unexpectedly vulnerable to lysosomal membrane destabilization. MDGI silencing impaired trafficking of polyunsaturated fatty acids into cells resulting in significant alterations in the lipid composition of lysosomal membranes, and subsequent death of the patient-derived glioma cells via lysosomal membrane permeabilization (LMP). In a preclinical model, treatment of glioma-bearing mice with an antihistaminergic LMP-inducing drug efficiently eradicated invasive glioma cells and secondary tumours within the brain. This unexpected fragility of the aggressive infiltrating cells to LMP provides new opportunities for clinical interventions, such as re-positioning of an established antihistamine drug, to eradicate the inoperable, invasive, and chemo-resistant glioma cells from sustaining disease progression and recurrence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available